Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

Cardiovascular Drugs and Therapy

Volumn 31, Issue 2, 2017, Pages 197-208

  Ferretti, Gianna ^a   Bacchetti, Tiziana ^a   Simental Mendía, Luis E ^b   Reiner, Željko ^c   Banach, Maciej ^d   Sahebkar, Amirhossein ^e,f,g  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c KBC Zagreb   (Croatia)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cardiovascular diseases; Estrogen receptor modulators; Lipoprotein(a); Menopause; Raloxifene

Indexed keywords

LIPOPROTEIN A; RALOXIFENE; BIOLOGICAL MARKER; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MEDLINE; META ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SYSTEMATIC REVIEW; WEB OF SCIENCE; AGED; BLOOD; DOWN REGULATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TIME FACTOR;

ADMINISTRATION, ORAL; AGED; BIOMARKERS; DOWN-REGULATION; FEMALE; HUMANS; LIPOPROTEIN(A); MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE HYDROCHLORIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 85014527852     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-017-6721-6     Document Type: Review

References (70)

1. Bagger YZ, Rasmussen HB, Alexandersen P, Werge T, Christiansen C, Tanko LB. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int. 2007;18(4):505–12.
2. Manson JE, Bassuk SS. Biomarkers of cardiovascular disease risk in women. Metabolism. 2015;64(3 Suppl 1):S33–9.
3. Sprini D, Rini GB, Di Stefano L, Cianferotti L, Napoli N. Correlation between osteoporosis and cardiovascular disease. Clin Cases Miner Bone Metab. 2014;11(2):117–9.
4. Maziere C, Louvet L, Gomila C, Kamel S, Massy Z, Maziere JC. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. J Cell Physiol. 2009;221(3):572–8.
5. Orozco P. Atherogenic lipid profile and elevated lipoprotein (a) are associated with lower bone mineral density in early postmenopausal overweight women. Eur J Epidemiol. 2004;19(12):1105–12.
6. Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, et al. A metabolic view on menopause and ageing. Nat Commun. 2014;5.
7. Akahoshi M, Soda M, Nakashima E, Shimaoka K, Seto S, Yano K. Effects of menopause on trends of serum cholesterol, blood pressure, and body mass index. Circulation. 1996;94(1):61–6.
8. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab. 1988;67(1):30–5.
9. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PW, Castelli WP, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993;87(4):1135–41.
10. Berg G, Mesch V, Boero L, Sayegh F, Prada M, Royer M, et al. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution. Horm Metab Res. 2004;36(4):215–20.
11. Boffa MB, Koschinsky ML. Update on lipoprotein(a) as a cardiovascular risk factor and mediator. Curr Atheroscler Rep. 2013;15(10):360.
12. Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23(2):133–40.
13. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–23.
14. Kronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30(1):87-100.
15. Kostner KM, Marz W, Kostner GM. When should we measure lipoprotein (a)? Eur Heart J. 2013;34(42):3268–76.
16. Marcovina SM, Hegele RA, Koschinsky ML. Lipoprotein(a) and coronary heart disease risk. Current Cardiol Reports. 1999;1(2):105–11.
17. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi:10.1093/eurheartj/ehw272.
18. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53. doi:10.1093/eurheartj/ehq386.
19. Morishita R, Ishii J, Kusumi Y, Yamada S, Komai N, Ohishi M, et al. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vasucular wall. J Atheroscler Thromb. 2009;16(4):410–8.
20. Wei DH, Zhang XL, Wang R, Zeng JF, Zhang K, Yang J, et al. Oxidized lipoprotein(a) increases endothelial cell monolayer permeability via ROS generation. Lipids. 2013;48(6):579–86.
21. Francucci CM, Romagni P, Boscaro M. Raloxifene: bone and cardiovascular effects. J Endocrinol Invest. 2005;28(10 Suppl):85–9.
22. Dayspring T, Qu Y, Keech C. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism. 2006;55(7):972–9.
23. Higgins JPT, Green S. Handbook for systematic reviews of interventions. Version 5.0.2 ed. London: The Cochrane Collboration; 2009.
24. Borenstein M, Hedges L, Higgins JPT. Comprehensive meta-analysis. Version 2. Englewood: Biostat; 2005.
25. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
26. Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50–73.
27. Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Watts GF, Blumenthal RS, Lip GY, Mikhailidis DP, Sahebkar A. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res. 2015;99:329–36.
28. Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, Rysz J, Toth PP, Muntner P, Mosteoru S, García-García HM, Hovingh GK, Kastelein JJ, Serruys PW. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.
29. Sahebkar A. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. 2014;28(5):633–42.
30. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63.
31. Mijatovic V, van der Mooren MJ, Kenemans P, de Walk-de Roo GW, Netelenbos C. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause. 1999;6(2):134–7.
32. Smolders RGV, Vogelvang TE, Mijatovic V, van Baal WM, Neele SJM, Netelenbos JC, et al. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas. 2002;41(2):105–14.
33. Vogelvang TE, Mijatovic V, Kenemans P, Teerlink T, van der Mooren MJ. HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women. Fertil Steril. 2004;82(6):1540–9.
34. Andersson B, Johannsson G, Holm G, Bengtsson BA, Sashegyi A, Pavo I, et al. Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab. 2002;87(1):122–8.
35. Insull W, Davidson MH, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. Metab Clin Exp. 2005;54(7):939–46.
36. Lobo RA, Pinkerton JV, Gass MLS, Dorin MH, Ronkin S, Pickar JH, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92(3):1025–38.
37. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279(18):1445–51.
38. Riches K, Porter KE. Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol. 2012;2012:923289.
39. Maranhao R, Arie S, Vinagre CG, Guimaraes JB, Strunz C, Pileggi F. Lipoprotein (a) plasma levels in normal subjects and patients with coronary disease confirmed by coronary cineangiography. Arq Bras Cardiol. 1991;56(2):121–5.
40. Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol. 2014;25(6):452–60.
41. Hoover-Plow J, Huang MG. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metab Clin Exp. 2013;62(4):479–91.
42. Bacchetti T, Campanati A, Ferretti G, Simonetti O, Liberati G, Offidani AM. Oxidative stress and psoriasis: the effect of antitumour necrosis factor-alpha inhibitor treatment. Br J Dermatol. 2013;168(5):984–9. doi:10.1111/bjd.12144.
43. Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Scientific reports. 2016;6:19188. doi:10.1038/srep19188.
44. Sahebkar A, Simental-Mendia LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198–209. doi:10.1016/j.phrs.2016.01.030.
45. Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women—influence of various progestogens and duration of therapy. Arch Intern Med. 1996;156(15):1693–700.
46. Salpeter SR, Walsh JME, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538–54.
47. Sahebkar A, Reiner Z, Simental-Mendia LE, Ferretti G, Cicero AF. Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664–78. doi:10.1016/j.metabol.2016.08.007.
48. Kotani K, Sahebkar A, Serban C, Andrica F, Toth PP, Jones SR, et al. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: a systematic review and meta-analysis of 12 studies with 1009 patients. Atherosclerosis. 2015;242(1):87–96.
49. Maranhao RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76–83.
50. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Cl Lab Sci. 1996;33(6):495–543.
51. Rader DJ, Cain W, Zech LA, Usher D, Brewer Jr HB. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993;91(2):443–7. doi:10.1172/JCI116221.
52. Boffelli D, Zajchowski DA, Yang Z, Lawn RM. Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. J Biol Chem. 1999;274(22):15569–74.
53. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res. 1997;48(4):155–63.
54. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287(7):847–57.
55. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355(2):125–37. doi:10.1056/NEJMoa062462.
56. Saitta A, Morabito N, Frisina N, Cucinotte D, Corrado F, D’Anna R, et al. Cardiovascular effects of raloxifene hydrochloride. Cardiovasc Drug Rev. 2001;19(1):57–74.
57. Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscl Throm Vas. 2001;21(9):1512–9.
58. Resch U, Mellauner V, Budinsky A, Sinzinger H. Inhibition of low-density lipoprotein and high-density lipoprotein oxidation by raloxifene. J Womens Health (Larchmt). 2004;13(4):404–11.
59. Zuckerman SH, Bryan N. Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL). Atherosclerosis. 1996;126(1):65–75.
60. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation. 1999;100(10):1095–101.
61. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab. 2000;85(8):2966–9. doi:10.1210/jcem.85.8.6853.
62. Fu Z, Luo B, Li M, Peng B, Wang Z. Effects of raloxifene on the proliferation and apoptosis of human aortic valve interstitial cells. Biomed Res Int. 2016;2016:5473204. doi:10.1155/2016/5473204.
63. Hansdottir H. Raloxifene for older women: a review of the literature. Clin Interv Aging. 2008;3(1):45–50.
64. Messalli EM, Scaffa C. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health. 2010;1:11–20.
65. Jacobson TA. Lipoprotein(a), cardiovascular disease, and contemporary management. Mayo Clin Proc. 2013;88(11):1294–311.
66. Banach M, Serban C, Aronow WS, Rysz J, Dragan S, Lerma EV, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014;46(5):947–61.
67. Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res. 2014;56:47–66.
68. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmaco. 2014;15(4):493–503.
69. Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082–98.
70. Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drug Ther. 2013;27(6):559–67.